AI in Precision Medicine Market Report 2026

The artificial intelligence (AI) in precision medicine market size has grown exponentially in recent years. It will grow from $2.98 billion in 2025 to $3.93 billion in 2026 at a compound annual growth rate (CAGR) of 31.8%. The growth in the historic period can be attributed to growth in genomic sequencing data, advancements in healthcare analytics, increasing prevalence of chronic diseases, demand for personalized therapies, expansion of digital health records.

The artificial intelligence (AI) in precision medicine market size is expected to see exponential growth in the next few years. It will grow to $12.02 billion in 2030 at a compound annual growth rate (CAGR) of 32.2%. The growth in the forecast period can be attributed to integration of AI with genomics research, growth of personalized medicine adoption, increasing investment in precision healthcare, rising use of real world evidence, advancements in clinical AI platforms. Major trends in the forecast period include AI driven genomic data analysis, personalized treatment recommendation systems, predictive disease risk modeling, clinical decision support automation, real time patient data integration.

The growing prevalence of chronic illnesses and respiratory disorders is anticipated to drive the expansion of the artificial intelligence in precision medicine market in the coming years. Chronic illnesses are defined as medical conditions that persist for more than a year and demand continuous medical care, while respiratory disorders include diseases affecting the airways and lungs. Artificial intelligence in precision medicine supports the diagnosis and outcome prediction for patients with respiratory conditions using clinical information and chest imaging. It is also applied in the treatment of chronic diseases as it lowers costs and enhances the efficient use of resources. For example, in May 2023, the United Nations, a US-based intergovernmental organization, projected that chronic diseases such as cardiovascular conditions, cancer, diabetes, and respiratory illnesses would contribute to 86% of the 90 million deaths by 2050. Additionally, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the mortality rate linked to chronic conditions rose by 490 deaths per 100,000 people in 2022. Hence, the increasing burden of chronic illnesses and respiratory diseases is expected to propel the artificial intelligence in precision medicine market.

Leading companies operating in the artificial intelligence (AI) in precision medicine market are concentrating on the development of advanced AI-based life sciences solutions, such as protein structure prediction suites, to speed up drug discovery, strengthen target identification, and enhance the efficiency of personalized treatment development. Protein structure prediction suites are AI-driven tools that precisely model the three-dimensional structures of proteins, thereby supporting faster drug discovery and better understanding of biological processes. For instance, in May 2023, Google LLC, a US-based technology company, launched an AI-based life sciences solution named the Target and Lead Identification Suite, aimed at accelerating in silico drug development. This suite enables research teams to predict protein structures and accurately identify amino acid functions, improving the speed and accuracy of drug discovery and development within the precision medicine domain.

In July 2023, BioNTech SE, a Germany-based biotechnology company, acquired InstaDeep Ltd. for approximately £362 million. With this acquisition, BioNTech seeks to enhance its AI-driven drug discovery and development capabilities by incorporating InstaDeep’s advanced artificial intelligence and machine learning technologies. InstaDeep Ltd. is a UK-based technology firm that offers AI-powered decision-making and machine learning solutions for drug discovery and development.

Major companies operating in the artificial intelligence (AI) in precision medicine market are Alphabet Inc.; Microsoft Corporation; Intel Corporation; International Business Machines Corporation; AstraZeneca PLC; Sanofi S.A.; NVIDIA Corporation; GE HealthCare Technologies Inc.; Illumina Inc.; QIAGEN N.V.; Helix Inc.; Sema4 Holdings Corp.; SOPHiA GENETICS SA; Insilico Medicine; BenevolentAI Limited; Fabric Genomics Inc.; Tempus Technologies Inc.; Enlitic Inc.; PathAI Inc.; Genuity Science Inc.; BERG LLC; Perthera Inc.; Vuno Inc.; CureMetrix Inc.; Zephyr AI; Freenome Inc.; PetaGene Ltd.; BioXcel Therapeutics Inc.

North America was the largest region in the artificial intelligence (AI) in the precision medicine market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) in precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the AI in precision medicine market by increasing costs associated with imported diagnostic equipment, high performance computing systems, and data storage infrastructure. These impacts are more visible in research intensive regions such as North America, Europe, and Asia Pacific. Higher costs have affected deployment timelines for some healthcare providers. At the same time, tariffs are accelerating cloud based analytics adoption and local innovation. This trend is strengthening regional precision medicine ecosystems and long term scalability.

The artificial intelligence (AI) in precision medicine market research report is one of a series of new reports that provides artificial intelligence (AI) in precision medicine market statistics, including artificial intelligence (AI) in precision medicine industry global market size, regional shares, competitors with a artificial intelligence (AI) in precision medicine market share, detailed artificial intelligence (AI) in precision medicine market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in precision medicine industry. This artificial intelligence (AI) in precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In precision medicine, artificial intelligence involves leveraging advanced computation and inference to generate insights, enabling systems to reason, learn, and assist healthcare professionals in decision-making through augmented intelligence. Its application in precision medicine aims to optimize diagnosis, therapeutic intervention, and prognosis within the healthcare sector.

The primary components of artificial intelligence (AI) in precision medicine encompass hardware, software, and services. Hardware pertains to the physical components of a system or the mechanisms involved in storing and executing the instructions embedded in the application's software. Various technologies, such as deep learning, querying methods, natural language processing, and context-aware processing, are employed in diverse therapeutic applications, including oncology, cardiology, neurology, respiratory, and others.

The artificial intelligence in the precision medicine market consists of revenues earned by entities providing artificial intelligence in precision medicine services that include personalized treatment, disease prevention, and personalized diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence in the precision medicine market also includes sales of wearable devices, implantable devices, and artificial intelligence devices in precision medicine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.